{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T15:39:33Z","timestamp":1790437173948,"version":"4.1.0"},"reference-count":263,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T00:00:00Z","timestamp":1629331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"abstract":"<jats:p>Duchenne muscular dystrophy (DMD) is a lethal, X-linked neuromuscular disorder caused by the absence of dystrophin protein, which is essential for muscle fiber integrity. Loss of dystrophin protein leads to recurrent myofiber damage, chronic inflammation, progressive fibrosis, and dysfunction of muscle stem cells. There is still no cure for DMD so far and the standard of care is principally limited to symptom relief through glucocorticoids treatments. Current therapeutic strategies could be divided into two lines. Dystrophin-targeted therapeutic strategies that aim at restoring the expression and\/or function of dystrophin, including gene-based, cell-based and protein replacement therapies. The other line of therapeutic strategies aims to improve muscle function and quality by targeting the downstream pathological changes, including inflammation, fibrosis, and muscle atrophy. This review introduces the important developments in these two lines of strategies, especially those that have entered the clinical phase and\/or have great potential for clinical translation. The rationale and efficacy of each agent in pre-clinical or clinical studies are presented. Furthermore, a meta-analysis of gene profiling in DMD patients has been performed to understand the molecular mechanisms of DMD.<\/jats:p>","DOI":"10.3389\/fcell.2021.689533","type":"journal-article","created":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T13:25:09Z","timestamp":1629379509000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":60,"title":["Current Pharmacological Strategies for Duchenne Muscular Dystrophy"],"prefix":"10.3389","volume":"9","author":[{"given":"Shanshan","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hewen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongkang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,8,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1136\/jmedgenet-2015-103387","article-title":"The importance of genetic diagnosis for Duchenne muscular dystrophy.","volume":"53","author":"Aartsma-Rus","year":"2016","journal-title":"J. Med. Genet."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1093\/hmg\/ddt514","article-title":"Restoration of muscle strength in dystrophic muscle by angiotensin-1-7 through inhibition of TGF-\u03b2 signalling.","volume":"23","author":"Acu\u00f1a","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/ph14020145","article-title":"2020 FDA TIDES (peptides and oligonucleotides) harvest.","volume":"14","author":"Al Musaimi","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1152\/physrev.00007.2015","article-title":"Absence of dystrophin disrupts skeletal muscle signaling: roles of ca2+, reactive oxygen species, and nitric oxide in the development of muscular dystrophy.","volume":"96","author":"Allen","year":"2016","journal-title":"Physiol. Rev."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1371\/currents.md.2cc69a1dae4be7dfe2bcb420024ea865","article-title":"A randomized, double-blind trial of lisinopril and losartan for the treatment of cardiomyopathy in duchenne muscular dystrophy.","volume":"5","author":"Allen","year":"2013","journal-title":"PLoS Curr."},{"key":"B6","doi-asserted-by":"publisher","first-page":"20876","DOI":"10.1074\/jbc.M112.344929","article-title":"Increased resting intracellular calcium modulates NF-\u03baB-dependent inducible nitric-oxide synthase gene expression in dystrophic mdx skeletal myotubes.","volume":"287","author":"Altamirano","year":"2012","journal-title":"J. Biol. Chem."},{"key":"B7","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3233\/JND-150083","article-title":"Follistatin gene therapy improves ambulation in becker muscular dystrophy.","volume":"2","author":"Al-Zaidy","year":"2015","journal-title":"J. Neuromuscul. Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"282","DOI":"10.4103\/ijmr.IJMR_290_18","article-title":"Targeted sequencing of the DMD locus: a comprehensive diagnostic tool for all mutations.","volume":"150","author":"Aravind","year":"2019","journal-title":"Indian J. Med. Res."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0000806","article-title":"Primary role of functional ischemia, quantitative evidence for the two-hit mechanism, and phosphodiesterase-5 inhibitor therapy in mouse muscular dystrophy.","volume":"2","author":"Asai","year":"2007","journal-title":"PLoS One"},{"key":"B10","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1080\/14712598.2020.1725469","article-title":"Clinical development on the frontier: gene therapy for duchenne muscular dystrophy.","volume":"20","author":"Asher","year":"2020","journal-title":"Expert. Opin. Biol. Ther."},{"key":"B11","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid. Based Mental Health"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1172\/JCI11891","article-title":"Series introduction: the transcription factor NF-kappaB and human disease.","volume":"107","author":"Baldwin","year":"2001","journal-title":"J. Clin. Invest."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1000958","article-title":"The polyproline site in hinge 2 influences the functional capacity of truncated dystrophins.","volume":"6","author":"Banks","year":"2010","journal-title":"PLoS Genet."},{"key":"B14","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/nrg2918","article-title":"Network medicine: a network-based approach to human disease.","volume":"12","author":"Barab\u00e1si","year":"2011","journal-title":"Nat. Rev. Genet."},{"key":"B15","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.1073\/pnas.1620982114","article-title":"Gentamicin B1 is a minor gentamicin component with major nonsense mutation suppression activity.","volume":"114","author":"Baradaran-Heravi","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B16","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1083\/jcb.200108071","article-title":"Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice.","volume":"157","author":"Barton","year":"2002","journal-title":"J. Cell Biol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"5723","DOI":"10.1073\/pnas.1323842111","article-title":"Microtubule binding distinguishes dystrophin from utrophin.","volume":"111","author":"Belanto","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B18","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8050649","article-title":"The \u201cUsual Suspects\u201d: genes for inflammation, fibrosis, regeneration, and muscle strength modify duchenne muscular dystrophy","volume":"8","author":"Bello","year":"2019","journal-title":"J. Clin. Med."},{"key":"B19","article-title":"Safety and efficacy of PF-06939926 gene therapy in boys with Duchenne muscular dystrophy: update on data from the phase 1b study","author":"Belluscio","year":"2021","journal-title":"Proceedings of the MDA Clinical and Scientific Conference 2021"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms16007","article-title":"Muscle-specific CRISPR\/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy.","volume":"8","author":"Bengtsson","year":"2017","journal-title":"Nat. Commun."},{"key":"B21","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.nmd.2016.07.002","article-title":"Histological effects of givinostat in boys with Duchenne muscular dystrophy.","volume":"26","author":"Bettica","year":"2016","journal-title":"Neuromuscul. Disord."},{"key":"B22","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s00198-003-1443-y","article-title":"Bone mineral density and bone metabolism in Duchenne muscular dystrophy.","volume":"14","author":"Bianchi","year":"2003","journal-title":"Osteoporos. Int."},{"key":"B23","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.nmd.2006.01.010","article-title":"Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade.","volume":"16","author":"Biggar","year":"2006","journal-title":"Neuromuscul. Disord."},{"key":"B24","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1474-4422(18)30025-5","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management.","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0020856","article-title":"Chronic losartan administration reduces mortality and preserves cardiac but not skeletal muscle function in dystrophic mice.","volume":"6","author":"Bish","year":"2011","journal-title":"PLoS One"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21197056","article-title":"Multi-compartment, early disruption of cGMP and cAMP signalling in cardiac myocytes from the mdx model of duchenne muscular dystrophy.","volume":"21","author":"Brescia","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/928385","article-title":"Optimizing bone health in duchenne muscular dystrophy.","volume":"2015","author":"Buckner","year":"2015","journal-title":"Int. J. Endocrinol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"5175","DOI":"10.1113\/JP276954","article-title":"Recovery of respiratory function in mdx mice co-treated with neutralizing interleukin-6 receptor antibodies and urocortin-2.","volume":"596","author":"Burns","year":"2018","journal-title":"J. Physiol."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2017.06.358","article-title":"AT-300, a calcium modulator, improves muscle force production and decreases muscle degeneration in D2-mdx model of Duchenne muscular dystrophy.","volume":"27","author":"Bush","year":"2017","journal-title":"Neuromusc. Disord."},{"key":"B30","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1093\/eurheartj\/ehn406","article-title":"Long-term blinded placebo-controlled study of SNT-MC17\/idebenone in the dystrophin deficient mdx mouse: cardiac protection and improved exercise performance.","volume":"30","author":"Buyse","year":"2009","journal-title":"Eur. Heart J."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1016\/S0140-6736(15)60025-3","article-title":"Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial.","volume":"385","author":"Buyse","year":"2015","journal-title":"Lancet"},{"key":"B32","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/ncb1812","article-title":"MG53 nucleates assembly of cell membrane repair machinery.","volume":"11","author":"Cai","year":"2009","journal-title":"Nat. Cell Biol."},{"key":"B33","doi-asserted-by":"crossref","first-page":"4717","DOI":"10.1002\/jcb.26651","article-title":"Down-regulation of FN1 inhibits colorectal carcinogenesis by suppressing proliferation, migration, and invasion","volume":"119","author":"Cai","year":"2018","journal-title":"J. Cell. Biochem."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/j.ymthe.2017.02.019","article-title":"Progress toward gene therapy for duchenne muscular dystrophy.","volume":"25","author":"Chamberlain","year":"2017","journal-title":"Mol. Ther."},{"key":"B35","doi-asserted-by":"publisher","first-page":"29691","DOI":"10.1073\/pnas.2018391117","article-title":"Degenerative and regenerative pathways underlying Duchenne muscular dystrophy revealed by single-nucleus RNA sequencing.","volume":"117","author":"Chemello","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B36","doi-asserted-by":"publisher","first-page":"H381","DOI":"10.1152\/ajpheart.00602.2003","article-title":"Inhibition and reversal of myocardial infarction-induced hypertrophy and heart failure by NHE-1 inhibition.","volume":"286","author":"Chen","year":"2004","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"G744","DOI":"10.1152\/ajpgi.00339.2018","article-title":"Multitranscriptome analyses reveal prioritized genes specifically associated with liver fibrosis progression independent of etiology.","volume":"316","author":"Chen","year":"2019","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"B38","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.593269","article-title":"Connective tissue growth factor: from molecular understandings to drug discovery","volume":"8","author":"Chen","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/mt.2013.246","article-title":"Vascular delivery of rAAVrh74.MCK.GALGT2 to the gastrocnemius muscle of the rhesus macaque stimulates the expression of dystrophin and laminin \u03b12 surrogates.","volume":"22","author":"Chicoine","year":"2014","journal-title":"Mol. Ther."},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1186\/1752-0509-8-S4-S11","article-title":"cytoHubba: identifying hub objects and sub-networks from complex interactome.","author":"Chin","year":"2014","journal-title":"BMC Syst. Biol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S0140-6736(11)60756-3","article-title":"Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study.","volume":"378","author":"Cirak","year":"2011","journal-title":"Lancet"},{"key":"B42","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1001\/jamaneurol.2020.1264","article-title":"Safety, tolerability, and efficacy of viltolarsen in boys with duchenne muscular dystrophy amenable to exon 53 skipping: a phase 2 randomized clinical trial.","volume":"77","author":"Clemens","year":"2020","journal-title":"JAMA Neurol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nm1536","article-title":"Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states.","volume":"13","author":"Cohn","year":"2007","journal-title":"Nat. Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"19183","DOI":"10.1073\/pnas.0805514105","article-title":"HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment.","volume":"105","author":"Colussi","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B45","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.phrs.2013.03.003","article-title":"GLPG0492, a novel selective androgen receptor modulator, improves muscle performance in the exercised-mdx mouse model of muscular dystrophy.","volume":"72","author":"Cozzoli","year":"2013","journal-title":"Pharmacol. Res."},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-01430-8","article-title":"Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis.","volume":"15","author":"Crisafulli","year":"2020","journal-title":"Orphanet. J. Rare Dis."},{"key":"B47","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/prca.201300072","article-title":"Fibronectin is a serum biomarker for Duchenne muscular dystrophy.","volume":"8","author":"Cynthia Martin","year":"2014","journal-title":"Proteomics Clin. Appl."},{"key":"B48","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1002\/mus.23858","article-title":"Suramin attenuates dystrophin-deficient cardiomyopathy in the mdx mouse model of duchenne muscular dystrophy.","volume":"48","author":"De Oliveira Moreira","year":"2013","journal-title":"Muscle Nerve"},{"key":"B49","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/mus.25199","article-title":"P2Y(2) purinergic receptors are highly expressed in cardiac and diaphragm muscles of mdx mice, and their expression is decreased by suramin.","volume":"55","author":"De Oliveira Moreira","year":"2017","journal-title":"Muscle Nerve"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1212\/WNL.0b013e3182518302","article-title":"Increased muscle expression of interleukin-17 in Duchenne muscular dystrophy.","volume":"78","author":"De Pasquale","year":"2012","journal-title":"Neurology"},{"key":"B51","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.clnu.2012.06.001","article-title":"N-acetylcysteine treatment reduces TNF-\u03b1 levels and myonecrosis in diaphragm muscle of mdx mice.","volume":"32","author":"de Senzi Moraes Pinto","year":"2013","journal-title":"Clin. Nutr."},{"key":"B52","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1097\/NEN.0b013e3181aa31c2","article-title":"Endomysial fibrosis in Duchenne muscular dystrophy: a marker of poor outcome associated with macrophage alternative activation.","volume":"68","author":"Desguerre","year":"2009","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.nmd.2018.09.001","article-title":"Role of neuronal nitric oxide synthase (nNOS) in Duchenne and Becker muscular dystrophies \u2013 Still a possible treatment modality?","volume":"28","author":"Dombernowsky","year":"2018","journal-title":"Neuromuscul. Disord."},{"key":"B54","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1002\/jcph.842","article-title":"A novel NF-\u03baB Inhibitor, edasalonexent (CAT-1004), in development as a disease-modifying treatment for patients with duchenne muscular dystrophy: phase 1 safety, pharmacokinetics, and pharmacodynamics in adult subjects.","volume":"57","author":"Donovan","year":"2017","journal-title":"J. Clin. Pharmacol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.ajpath.2012.10.018","article-title":"The anticancer drug tamoxifen counteracts the pathology in a mouse model of duchenne muscular dystrophy.","volume":"182","author":"Dorchies","year":"2013","journal-title":"Am. J. Pathol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2147\/RRB.S13463","article-title":"Duchenne muscular dystrophy gene therapy: lost in translation?","volume":"2011","author":"Duan","year":"2011","journal-title":"Res. Rep. Biol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1016\/j.ymthe.2018.07.011","article-title":"Systemic AAV micro-dystrophin gene therapy for duchenne muscular dystrophy.","volume":"26","author":"Duan","year":"2018","journal-title":"Mol. Ther."},{"key":"B58","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1242\/dmm.019216","article-title":"Early loss of ambulation is not a representative clinical feature in Duchenne muscular dystrophy dogs: remarks on the article of Barth\u00e9l\u00e9my et al.","volume":"8","author":"Duan","year":"2015","journal-title":"Dis. Model Mech."},{"key":"B59","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/s41434-020-0156-6","article-title":"Optimization of antisense-mediated exon skipping for Duchenne muscular dystrophy.","volume":"27","author":"Dzierlega","year":"2020","journal-title":"Gene Ther."},{"key":"B60","doi-asserted-by":"publisher","first-page":"R163","DOI":"10.1093\/hmg\/ddy171","article-title":"Exon-skipping advances for Duchenne muscular dystrophy.","volume":"27","author":"Echevarr\u00eda","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2014.76","article-title":"Long-term efficacy of systemic multiexon skipping targeting dystrophin exons 45-55 with a cocktail of vivo-morpholinos in mdx52 mice.","volume":"4","author":"Echigoya","year":"2015","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B62","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.nmd.2014.04.006","article-title":"Long-term administration of the TNF blocking drug remicade (cV1q) to mdx mice reduces skeletal and cardiac muscle fibrosis, but negatively impacts cardiac function.","volume":"24","author":"Ermolova","year":"2014","journal-title":"Neuromuscul. Disord."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1073\/pnas.0908540107","article-title":"Leaky RyR2 trigger ventricular arrhythmias in Duchenne muscular dystrophy.","volume":"107","author":"Fauconnier","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B64","doi-asserted-by":"publisher","first-page":"6545","DOI":"10.3390\/ijms16036545","article-title":"The potential of the combination of CRISPR\/Cas9 and pluripotent stem cells to provide human organs from chimaeric pigs.","volume":"16","author":"Feng","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0081302","article-title":"Phase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation Duchenne muscular dystrophy.","volume":"8","author":"Finkel","year":"2013","journal-title":"PLoS One"},{"key":"B66","doi-asserted-by":"publisher","first-page":"e2270","DOI":"10.1212\/WNL.0000000000009233","article-title":"Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy.","volume":"94","author":"Frank","year":"2020","journal-title":"Neurology"},{"key":"B67","doi-asserted-by":"publisher","first-page":"13663","DOI":"10.1073\/pnas.1512991112","article-title":"Dystrophin-glycoprotein complex regulates muscle nitric oxide production through mechanoregulation of AMPK signaling.","volume":"112","author":"Garbincius","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B68","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ijcard.2020.03.031","article-title":"Protective effects of rimeporide on left ventricular function in golden retriever muscular dystrophy dogs.","volume":"312","author":"Ghaleh","year":"2020","journal-title":"Int. J. Cardiol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"S215","DOI":"10.1016\/j.nmd.2017.06.438","article-title":"P.398 - Rimeporide: safety, tolerability and pharmacokinetic results from a phase Ib study in DMD boys as well as exploratory biomarkers.","volume":"27","author":"Gidaro","year":"2017","journal-title":"Neuromuscul. Disord."},{"key":"B70","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1212\/WNL.0000000000002337","article-title":"Practice guideline update summary: corticosteroid treatment of duchenne muscular dystrophy: report of the guideline development subcommittee of the american academy of neurology.","volume":"86","author":"Gloss","year":"2016","journal-title":"Neurology"},{"key":"B71","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.ejpn.2019.09.008","article-title":"Psychosocial adjustment and parental stress in duchenne muscular dystrophy.","volume":"23","author":"Gocheva","year":"2019","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"5911","DOI":"10.1007\/s12035-019-1490-9","article-title":"CTGF\/CCN2 from skeletal muscle to nervous system: impact on neurodegenerative diseases.","volume":"56","author":"Gonzalez","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1016\/S0002-9440(10)64502-6","article-title":"Improved contractile function of the mdx dystrophic mouse diaphragm muscle after insulin-like growth factor-I administration.","volume":"161","author":"Gregorevic","year":"2002","journal-title":"Am. J. Pathol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1096\/fj.03-1024com","article-title":"Anti-TNFalpha (Remicade) therapy protects dystrophic skeletal muscle from necrosis.","volume":"18","author":"Grounds","year":"2004","journal-title":"FASEB J."},{"key":"B75","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.coph.2017.04.002","article-title":"Pharmacological advances for treatment in Duchenne muscular dystrophy.","volume":"34","author":"Guiraud","year":"2017","journal-title":"Curr. Opin. Pharmacol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1093\/hmg\/ddz049","article-title":"The potential of utrophin and dystrophin combination therapies for Duchenne muscular dystrophy.","volume":"28","author":"Guiraud","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"B77","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1093\/hmg\/ddl018","article-title":"Absence of alpha 7 integrin in dystrophin-deficient mice causes a myopathy similar to Duchenne muscular dystrophy.","volume":"15","author":"Guo","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0147634","article-title":"Improved muscle function in duchenne muscular dystrophy through L-arginine and metformin: an investigator-initiated, open-label, single-center, proof-of-concept-study.","volume":"11","author":"Hafner","year":"2016","journal-title":"PLoS One"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.14171","article-title":"Effect of combination l-citrulline and metformin treatment on motor function in patients with duchenne muscular dystrophy: a randomized clinical trial.","volume":"2","author":"Hafner","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"B80","doi-asserted-by":"publisher","first-page":"4318","DOI":"10.1073\/pnas.0709144105","article-title":"Long-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitors.","volume":"105","author":"Haidet","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B81","doi-asserted-by":"crossref","DOI":"10.1007\/s12079-008-0023-5","article-title":"Functional role of periostin in development and wound repair: implications for connective tissue disease","volume":"2","author":"Hamilton","year":"2008","journal-title":"J. Cell Commun. Signal."},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.133276","article-title":"Glucocorticoids counteract hypertrophic effects of myostatin inhibition in dystrophic muscle.","volume":"5","author":"Hammers","year":"2020","journal-title":"JCI Insight"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.90341","article-title":"Disease-modifying effects of orally bioavailable NF-\u03baB inhibitors in dystrophin-deficient muscle.","volume":"1","author":"Hammers","year":"2016","journal-title":"JCI Insight"},{"key":"B84","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1097\/SPC.0b013e32834bddf9","article-title":"Targeting the myostatin signaling pathway to treat muscle wasting diseases.","volume":"5","author":"Han","year":"2011","journal-title":"Curr. Opin. Support Palliat Care"},{"key":"B85","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.nmd.2006.08.012","article-title":"Low dose formoterol administration improves muscle function in dystrophic mdx mice without increasing fatigue.","volume":"17","author":"Harcourt","year":"2007","journal-title":"Neuromuscul. Disord."},{"key":"B86","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.apmr.2004.04.021","article-title":"Alendronate in the treatment of low bone mass in steroid-treated boys with Duchennes muscular dystrophy.","volume":"86","author":"Hawker","year":"2005","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"B87","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41586-020-2938-9","article-title":"Fibrosis: from mechanisms to medicines.","volume":"587","author":"Henderson","year":"2020","journal-title":"Nature"},{"key":"B88","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s40265-020-01267-2","article-title":"Golodirsen: first approval.","volume":"80","author":"Heo","year":"2020","journal-title":"Drugs"},{"key":"B89","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41556-017-0010-2","article-title":"ERBB3 and NGFR mark a distinct skeletal muscle progenitor cell in human development and hPSCs.","volume":"20","author":"Hicks","year":"2018","journal-title":"Nat. Cell Biol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.2353\/ajpath.2008.071009","article-title":"L-arginine decreases inflammation and modulates the nuclear factor-kappaB\/matrix metalloproteinase cascade in mdx muscle fibers.","volume":"172","author":"Hnia","year":"2008","journal-title":"Am. J. Pathol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/eji.201747131","article-title":"CRISPR\/Cas9: a tool for immunological research.","volume":"48","author":"Hochheiser","year":"2018","journal-title":"Eur. J. Immunol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1126\/science.3659917","article-title":"Conservation of the Duchenne muscular dystrophy gene in mice and humans.","volume":"238","author":"Hoffman","year":"1987","journal-title":"Science"},{"key":"B93","doi-asserted-by":"publisher","first-page":"e1312","DOI":"10.1212\/WNL.0000000000008168","article-title":"Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function.","volume":"93","author":"Hoffman","year":"2019","journal-title":"Neurology"},{"key":"B94","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1097\/WCO.0000000000000241","article-title":"Viral vector-mediated gene therapies.","volume":"28","author":"Hollinger","year":"2015","journal-title":"Curr. Opin. Neurol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1007\/s00726-015-2018-x","article-title":"The L-arginine\/NO pathway and homoarginine are altered in Duchenne muscular dystrophy and improved by glucocorticoids.","volume":"47","author":"H\u00f6rster","year":"2015","journal-title":"Amino Acids"},{"key":"B96","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1096\/fj.09-129833","article-title":"Imatinib attenuates skeletal muscle dystrophy in mdx mice.","volume":"23","author":"Huang","year":"2009","journal-title":"FASEB J."},{"key":"B97","doi-asserted-by":"publisher","first-page":"H1550","DOI":"10.1152\/ajpheart.01253.2007","article-title":"Functional resolution of fibrosis in mdx mouse dystrophic heart and skeletal muscle by halofuginone.","volume":"294","author":"Huebner","year":"2008","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"B98","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1600-065X.2009.00798.x","article-title":"Galectin-3 regulates T-cell functions","volume":"230","author":"Hsu","year":"2009","journal-title":"Immunol. Rev."},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107719","article-title":"Current and emerging therapies for Duchenne muscular dystrophy and spinal muscular atrophy.","volume":"220","author":"Iftikhar","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"B100","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ymthe.2006.03.014","article-title":"Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8.","volume":"14","author":"Inagaki","year":"2006","journal-title":"Mol. Ther."},{"key":"B101","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1167\/iovs.14-15589","article-title":"Microarray analysis of gene expression in fibrovascular membranes excised from patients with proliferative diabetic retinopathy.","volume":"56","author":"Ishikawa","year":"2015","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"B102","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.nmd.2012.10.025","article-title":"Imatinib attenuates severe mouse dystrophy and inhibits proliferation and fibrosis-marker expression in muscle mesenchymal progenitors.","volume":"23","author":"Ito","year":"2013","journal-title":"Neuromuscul. Disord."},{"key":"B103","doi-asserted-by":"publisher","first-page":"4488","DOI":"10.21037\/tcr-19-2588","article-title":"Effect of AAV9-hIGF-1 on inflammatory reaction in mdx mice and its mechanism.","volume":"12","author":"Ji","year":"2020","journal-title":"Am. J. Transl. Res."},{"key":"B104","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity.","volume":"337","author":"Jinek","year":"2012","journal-title":"Science"},{"key":"B105","doi-asserted-by":"publisher","first-page":"3706","DOI":"10.1210\/en.2010-0150","article-title":"Effects of a novel selective androgen receptor modulator on dexamethasone-induced and hypogonadism-induced muscle atrophy.","volume":"151","author":"Jones","year":"2010","journal-title":"Endocrinology"},{"key":"B106","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.ajpath.2010.11.027","article-title":"Long-term blocking of calcium channels in mdx mice results in differential effects on heart and skeletal muscle.","volume":"178","author":"J\u00f8rgensen","year":"2011","journal-title":"Am. J. Pathol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"12267","DOI":"10.1002\/jcp.27972","article-title":"CRISPR\/Cas9 technology as a potent molecular tool for gene therapy.","volume":"234","author":"Karimian","year":"2019","journal-title":"J. Cell Physiol."},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2014.7","article-title":"Targeting TGF-\u03b2 signaling by antisense oligonucleotide-mediated knockdown of TGF-\u03b2 Type I receptor.","volume":"3","author":"Kemaladewi","year":"2014","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B109","doi-asserted-by":"publisher","first-page":"7028","DOI":"10.1073\/pnas.0710595105","article-title":"Sildenafil and cardiomyocyte-specific cGMP signaling prevent cardiomyopathic changes associated with dystrophin deficiency.","volume":"105","author":"Khairallah","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B110","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/S1474-4422(09)70211-X","article-title":"Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study.","volume":"8","author":"Kinali","year":"2009","journal-title":"Lancet Neurol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1073\/pnas.92.4.1108","article-title":"A sauvagine\/corticotropin-releasing factor receptor expressed in heart and skeletal muscle.","volume":"92","author":"Kishimoto","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B112","first-page":"184","article-title":"The role of fibrosis in Duchenne muscular dystrophy.","volume":"31","author":"Klingler","year":"2012","journal-title":"Acta Myol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/nature07414","article-title":"Sarcolemma-localized nNOS is required to maintain activity after mild exercise.","volume":"456","author":"Kobayashi","year":"2008","journal-title":"Nature"},{"key":"B114","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.addr.2015.05.008","article-title":"Exon skipping therapy for Duchenne muscular dystrophy.","volume":"87","author":"Kole","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B115","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/acn3.50978","article-title":"Early phase 2 trial of TAS-205 in patients with Duchenne muscular dystrophy.","volume":"7","author":"Komaki","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"3431","DOI":"10.1093\/hmg\/ddz181","article-title":"Spp1 (osteopontin) promotes TGF\u03b2 processing in fibroblasts of dystrophin-deficient muscles through matrix metalloproteinases.","volume":"28","author":"Kramerova","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"B117","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41434-021-00222-4","article-title":"Genome editing for Duchenne muscular dystrophy: a glimpse of the future?","volume":"28","author":"Kupatt","year":"2021","journal-title":"Gene Therapy"},{"key":"B118","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1172\/JCI36612","article-title":"Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy.","volume":"119","author":"Lai","year":"2009","journal-title":"J. Clin. Invest."},{"key":"B119","doi-asserted-by":"crossref","DOI":"10.3390\/cells8080815","article-title":"Osteopontin as a link between inflammation and cancer: the thorax in the spotlight","volume":"8","author":"Lamort","year":"2019","journal-title":"Cells"},{"key":"B120","doi-asserted-by":"publisher","first-page":"49831","DOI":"10.1074\/jbc.M204291200","article-title":"Myostatin inhibits myoblast differentiation by down-regulating MyoD expression.","volume":"277","author":"Langley","year":"2002","journal-title":"J. Biol. Chem."},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9020520","article-title":"Dysregulation of calcium handling in duchenne muscular dystrophy-associated dilated cardiomyopathy: mechanisms and experimental therapeutic strategies.","volume":"9","author":"Law","year":"2020","journal-title":"J. Clin. Med."},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2018.03.004","article-title":"Prevalence and long-term monitoring of humoral immunity against adeno-associated virus in Duchenne Muscular Dystrophy patients.","volume":"342","author":"Leborgne","year":"2019","journal-title":"Cell Immunol."},{"key":"B123","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.lfs.2015.10.023","article-title":"Chronic effects of losartan on the muscles and the serologic profiles of mdx mice.","volume":"143","author":"Lee","year":"2015","journal-title":"Life Sci."},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aay0271","article-title":"Applying genome-wide CRISPR-Cas9 screens for therapeutic discovery in facioscapulohumeral muscular dystrophy.","volume":"12","author":"Lek","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"B125","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/ana.24214","article-title":"Sildenafil does not improve cardiomyopathy in Duchenne\/Becker muscular dystrophy.","volume":"76","author":"Leung","year":"2014","journal-title":"Ann. Neurol."},{"key":"B126","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1242\/jcs.064808","article-title":"Sarcolemmal nNOS anchoring reveals a qualitative difference between dystrophin and utrophin.","volume":"123","author":"Li","year":"2010","journal-title":"J. Cell Sci."},{"key":"B127","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2147\/DDDT.S97635","article-title":"Eteplirsen in the treatment of Duchenne muscular dystrophy.","volume":"11","author":"Lim","year":"2017","journal-title":"Drug Des. Devel. Ther."},{"key":"B128","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1126\/science.aad5725","article-title":"Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy.","volume":"351","author":"Long","year":"2016","journal-title":"Science"},{"key":"B129","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1126\/science.1254445","article-title":"Prevention of muscular dystrophy in mice by CRISPR\/Cas9-mediated editing of germline DNA.","volume":"345","author":"Long","year":"2014","journal-title":"Science"},{"key":"B130","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/B978-0-12-800571-2.00009-8","article-title":"Chapter 9 \u2013 The effects of immune cell products (cytokines and hematopoietic cell growth factors) on bone cells","author":"Lorenzo","year":"2016","journal-title":"Osteoimmunology"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-60885-8","article-title":"High-throughput identification of post-transcriptional utrophin up-regulators for Duchenne muscle dystrophy (DMD) therapy.","volume":"10","author":"Loro","year":"2020","journal-title":"Sci. Rep."},{"key":"B132","article-title":"Type IV collagen drives alveolar epithelial-endothelial association and the morphogenetic movements of septation","volume":"14","author":"Loscertales","year":"2016","journal-title":"BMC Biol."},{"key":"B133","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1469-445X.2000.02018.x","article-title":"Power output of fast and slow skeletal muscles of mdx (dystrophic) and control mice after clenbuterol treatment.","volume":"85","author":"Lynch","year":"2000","journal-title":"Exp. Physiol."},{"key":"B134","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1016\/j.celrep.2017.06.005","article-title":"PAX7 Targets, CD54, Integrin \u03b19\u03b21, and SDC2, Allow Isolation of Human ESC\/iPSC-Derived Myogenic Progenitors.","volume":"19","author":"Magli","year":"2017","journal-title":"Cell Rep."},{"key":"B135","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.2147\/NDT.S93873","article-title":"Current and emerging treatment strategies for Duchenne muscular dystrophy.","volume":"12","author":"Mah","year":"2016","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"B136","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1002\/ana.22024","article-title":"Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy.","volume":"67","author":"Malik","year":"2010","journal-title":"Ann. Neurol."},{"key":"B137","doi-asserted-by":"publisher","first-page":"E134","DOI":"10.1002\/mus.25644","article-title":"Combined XIL-6R and urocortin-2 treatment restores MDX diaphragm muscle force.","volume":"56","author":"Manning","year":"2017","journal-title":"Muscle Nerve"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003725.pub4","article-title":"Corticosteroids for the treatment of Duchenne muscular dystrophy.","volume":"5","author":"Matthews","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.135703","article-title":"TGF-\u03b2-driven muscle degeneration and failed regeneration underlie disease onset in a DMD mouse model.","volume":"5","author":"M\u00e1zala","year":"2020","journal-title":"JCI Insight"},{"key":"B140","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/S0140-6736(17)31611-2","article-title":"Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"390","author":"McDonald","year":"2017","journal-title":"Lancet"},{"key":"B141","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1242\/dmm.018424","article-title":"Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy.","volume":"8","author":"McGreevy","year":"2015","journal-title":"Dis. Model Mech."},{"key":"B142","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1113\/jphysiol.2006.115352","article-title":"N-acetylcysteine attenuates the decline in muscle Na+,K+-pump activity and delays fatigue during prolonged exercise in humans.","volume":"576","author":"McKenna","year":"2006","journal-title":"J. Physiol."},{"key":"B143","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1002\/ana.21732","article-title":"Limb-girdle muscular dystrophy type 2D gene therapy restores alpha-sarcoglycan and associated proteins.","volume":"66","author":"Mendell","year":"2009","journal-title":"Ann. Neurol."},{"key":"B144","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1001\/jamaneurol.2020.1484","article-title":"Assessment of systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in children with duchenne muscular dystrophy: a nonrandomized controlled trial.","volume":"77","author":"Mendell","year":"2020","journal-title":"JAMA Neurol."},{"key":"B145","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/mt.2014.200","article-title":"A phase 1\/2a follistatin gene therapy trial for becker muscular dystrophy.","volume":"23","author":"Mendell","year":"2015","journal-title":"Mol. Ther."},{"key":"B146","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1038\/mt.2014.26","article-title":"Human skeletal muscle-derived CD133(+) cells form functional satellite cells after intramuscular transplantation in immunodeficient host mice.","volume":"22","author":"Meng","year":"2014","journal-title":"Mol. Ther."},{"key":"B147","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.scr.2018.05.004","article-title":"CD133+ cells derived from skeletal muscles of Duchenne muscular dystrophy patients have a compromised myogenic and muscle regenerative capability.","volume":"30","author":"Meng","year":"2018","journal-title":"Stem Cell Res."},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20174098","article-title":"Cardiac pathophysiology and the future of cardiac therapies in duchenne muscular dystrophy.","volume":"20","author":"Meyers","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B149","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.bbrc.2014.09.045","article-title":"Age-dependent changes in diastolic Ca(2+) and Na(+) concentrations in dystrophic cardiomyopathy: role of Ca(2+) entry and IP3.","volume":"452","author":"Mijares","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B150","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1146\/annurev-med-081117-010451","article-title":"CRISPR correction of duchenne muscular dystrophy.","volume":"70","author":"Min","year":"","journal-title":"Annu. Rev. Med."},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aav4324","article-title":"CRISPR-Cas9 corrects Duchenne muscular dystrophy exon 44 deletion mutations in mice and human cells.","volume":"5","author":"Min","year":"","journal-title":"Sci. Adv."},{"key":"B152","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/jgm.1265","article-title":"By-passing the nonsense mutation in the 4 CV mouse model of muscular dystrophy by induced exon skipping.","volume":"11","author":"Mitrpant","year":"2009","journal-title":"J. Gene Med."},{"key":"B153","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s12192-019-01039-2","article-title":"Coenzyme Q10 supplementation acts as antioxidant on dystrophic muscle cells.","volume":"24","author":"Mizobuti","year":"2019","journal-title":"Cell Stress Chaperones"},{"key":"B154","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/323646a0","article-title":"Isolation of candidate cDNAs for portions of the Duchenne muscular dystrophy gene.","volume":"323","author":"Monaco","year":"1986","journal-title":"Nature"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.034728","article-title":"Recapitulating muscle disease phenotypes with myotonic dystrophy 1 induced pluripotent stem cells: a tool for disease modeling and drug discovery.","volume":"11","author":"Mondragon-Gonzalez","year":"2018","journal-title":"Dis. Model Mech."},{"key":"B156","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s12079-017-0409-3","article-title":"The pro-fibrotic connective tissue growth factor (CTGF\/CCN2) correlates with the number of necrotic-regenerative foci in dystrophic muscle.","volume":"12","author":"Morales","year":"2018","journal-title":"J. Cell Commun. Signal."},{"key":"B157","doi-asserted-by":"publisher","first-page":"4938","DOI":"10.1093\/hmg\/ddt352","article-title":"Reducing CTGF\/CCN2 slows down mdx muscle dystrophy and improves cell therapy.","volume":"22","author":"Morales","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"B158","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.coph.2019.12.004","article-title":"Next-generation drug repurposing using human genetics and network biology.","volume":"51","author":"Nabirotchkin","year":"2020","journal-title":"Curr. Opin. Pharmacol."},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-019-3740-6","article-title":"Tamoxifen in Duchenne muscular dystrophy (TAMDMD): study protocol for a multicenter, randomized, placebo-controlled, double-blind phase 3 trial.","volume":"20","author":"Nagy","year":"2019","journal-title":"Trials"},{"key":"B160","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.cca.2013.03.031","article-title":"A prostaglandin D2 metabolite is elevated in the urine of Duchenne muscular dystrophy patients and increases further from 8 years old.","volume":"423","author":"Nakagawa","year":"2013","journal-title":"Clin. Chim. Acta"},{"key":"B161","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2147\/DNND.S71808","article-title":"Clinical potential of ataluren in the treatment of Duchenne muscular dystrophy.","volume":"6","author":"Namgoong","year":"2016","journal-title":"Degener. Neurol. Neuromuscul. Dis."},{"key":"B162","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1126\/science.aad5143","article-title":"In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy.","volume":"351","author":"Nelson","year":"2016","journal-title":"Science"},{"key":"B163","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/nrneurol.2017.126","article-title":"Genome engineering: a new approach to gene therapy for neuromuscular disorders.","volume":"13","author":"Nelson","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2020599118","article-title":"Ataluren and aminoglycosides stimulate read-through of nonsense codons by orthogonal mechanisms.","volume":"118","author":"Ng","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B165","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1242\/dmm.013631","article-title":"Molecular mechanism of sphingosine-1-phosphate action in Duchenne muscular dystrophy.","volume":"7","author":"Nguyen-Tran","year":"2014","journal-title":"Dis. Model. Mech."},{"key":"B166","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1080\/14712598.2017.1271872","article-title":"Exon skipping: a first in class strategy for Duchenne muscular dystrophy.","volume":"17","author":"Niks","year":"2017","journal-title":"Expert. Opin. Biol. Ther."},{"key":"B167","first-page":"447","article-title":"Epoxyeicosatrienoic acids and soluble epoxide hydrolase: potential therapeutic targets for inflammation and its induced carcinogenesis.","volume":"2","author":"Norwood","year":"2010","journal-title":"Am. J. Transl. Res."},{"key":"B168","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.1016\/j.bmc.2010.03.060","article-title":"Repairing faulty genes by aminoglycosides: development of new derivatives of geneticin (G418) with enhanced suppression of diseases-causing nonsense mutations.","volume":"18","author":"Nudelman","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"B169","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00292-017-0265-1","article-title":"[Molecular pathogenesis of Duchenne muscular dystrophy-related fibrosis].","volume":"38","author":"Ohlendieck","year":"2017","journal-title":"Pathologe"},{"key":"B170","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00439-019-02107-4","article-title":"Exon skipping induced by nonsense\/frameshift mutations in DMD gene results in Becker muscular dystrophy.","volume":"139","author":"Okubo","year":"2020","journal-title":"Hum. Genet."},{"key":"B171","doi-asserted-by":"publisher","first-page":"53857","DOI":"10.1074\/jbc.M409225200","article-title":"Solution structure and dynamics of a prototypical chordin-like cysteine-rich repeat (von Willebrand Factor type C module) from collagen IIA.","volume":"279","author":"O\u2019Leary","year":"2004","journal-title":"J. Biol. Chem."},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1186\/1755-8794-7-S3-S2","article-title":"Tumor antigens as proteogenomic biomarkers in invasive ductal carcinomas.","author":"Olsen","year":"2014","journal-title":"BMC Med. Genomics"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7244","article-title":"Multiplex CRISPR\/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy.","volume":"6","author":"Ousterout","year":"","journal-title":"Nat. Commun."},{"key":"B174","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/mt.2014.234","article-title":"Correction of dystrophin expression in cells from Duchenne muscular dystrophy patients through genomic excision of exon 51 by zinc finger nucleases.","volume":"23","author":"Ousterout","year":"","journal-title":"Mol. Ther."},{"key":"B175","doi-asserted-by":"publisher","first-page":"5090","DOI":"10.1096\/fj.201800081R","article-title":"Celecoxib treatment improves muscle function in mdx mice and increases utrophin A expression.","volume":"32","author":"P\u00e9ladeau","year":"2018","journal-title":"FASEB J."},{"key":"B176","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/978-3-642-17969-3_14","article-title":"Evaluation of the therapeutic utility of phosphodiesterase 5A inhibition in the mdx mouse model of duchenne muscular dystrophy.","volume":"204","author":"Percival","year":"2011","journal-title":"Handb. Exp. Pharmacol."},{"key":"B177","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/path.4054","article-title":"Sildenafil reduces respiratory muscle weakness and fibrosis in the mdx mouse model of Duchenne muscular dystrophy.","volume":"228","author":"Percival","year":"2012","journal-title":"J. Pathol."},{"key":"B178","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0883073816650034","article-title":"Fracture in duchenne muscular dystrophy: natural history and vitamin D deficiency.","volume":"31","author":"Perera","year":"2016","journal-title":"J. Child. Neurol."},{"key":"B179","doi-asserted-by":"publisher","first-page":"7093","DOI":"10.1113\/JP274229","article-title":"Pre-clinical evaluation of N-acetylcysteine reveals side effects in the mdx mouse model of Duchenne muscular dystrophy.","volume":"595","author":"Pinniger","year":"2017","journal-title":"J. Physiol."},{"key":"B180","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1089\/hum.2019.255","article-title":"Dose-escalation study of systemically delivered rAAVrh74.MHCK7.micro-dystrophin in the mdx mouse model of duchenne muscular dystrophy.","volume":"32","author":"Potter","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104999","article-title":"Rimeporide as a first- in-class NHE-1 inhibitor: results of a phase Ib trial in young patients with duchenne muscular dystrophy.","volume":"159","author":"Previtali","year":"2020","journal-title":"Pharmacol. Res."},{"key":"B182","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1183\/13993003.01030-2015","article-title":"FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis.","volume":"47","author":"Raghu","year":"2016","journal-title":"Eur. Respir. J."},{"key":"B183","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.matbio.2018.03.007","article-title":"Connective tissue growth factor (CTGF) from basics to clinics.","author":"Ramazani","year":"2018","journal-title":"Matrix Biol."},{"key":"B184","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1517\/21678707.2015.1088780","article-title":"Gene therapy for duchenne muscular dystrophy.","volume":"3","author":"Ramos","year":"2015","journal-title":"Expert. Opin. Orphan Drugs"},{"key":"B185","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.ymthe.2019.01.002","article-title":"Development of novel micro-dystrophins with enhanced functionality.","volume":"27","author":"Ramos","year":"2019","journal-title":"Mol. Ther."},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2020.119826","article-title":"Effects of exosome-mediated delivery of myostatin propeptide on functional recovery of mdx mice.","volume":"236","author":"Ran","year":"2020","journal-title":"Biomaterials"},{"key":"B187","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.ajpath.2011.10.038","article-title":"Urocortins improve dystrophic skeletal muscle structure and function through both PKA- and Epac-dependent pathways.","volume":"180","author":"Reutenauer-Patte","year":"2012","journal-title":"Am. J. Pathol."},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-48156-7","article-title":"Muscle satellite cells and impaired late stage regeneration in different murine models for muscular dystrophies.","volume":"9","author":"Ribeiro","year":"2019","journal-title":"Sci. Rep."},{"key":"B189","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1080\/17512433.2019.1634543","article-title":"New pharmacotherapies for genetic neuromuscular disorders: opportunities and challenges.","volume":"12","author":"Ricci","year":"2019","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"B190","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1161\/ATVBAHA.110.207449","article-title":"Prostaglandins and inflammation.","volume":"31","author":"Ricciotti","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0152840","article-title":"Safety, tolerability, and pharmacokinetics of SMT C1100, a 2-Arylbenzoxazole utrophin modulator, following single- and multiple-dose administration to pediatric patients with duchenne muscular dystrophy.","volume":"11","author":"Ricotti","year":"2016","journal-title":"PLoS One"},{"key":"B192","doi-asserted-by":"publisher","first-page":"C415","DOI":"10.1152\/ajpcell.00013.2017","article-title":"Expression of CTGF\/CCN2 in response to LPA is stimulated by fibrotic extracellular matrix via the integrin\/FAK axis.","volume":"314","author":"Riquelme-Guzm\u00e1n","year":"2018","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies.","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"B194","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1242\/jcs.02952","article-title":"Severe muscular dystrophy in mice that lack dystrophin and \u03b17 integrin.","volume":"119","author":"Rooney","year":"2006","journal-title":"J. Cell Sci."},{"key":"B195","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1002\/jbmr.410","article-title":"Mechanisms inducing low bone density in Duchenne muscular dystrophy in mice and humans.","volume":"26","author":"Rufo","year":"2011","journal-title":"J. Bone Miner. Res."},{"key":"B196","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/mus.26846","article-title":"Recombinant human insulin-like growth factor-1 therapy for 6 months improves growth but not motor function in boys with Duchenne muscular dystrophy.","volume":"61","author":"Rutter","year":"2020","journal-title":"Muscle Nerve"},{"key":"B197","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1007\/s40265-014-0287-4","article-title":"Ataluren: first global approval.","volume":"74","author":"Ryan","year":"2014","journal-title":"Drugs"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-05624-2","article-title":"Inhibition of CTGF ameliorates peritoneal fibrosis through suppression of fibroblast and myofibroblast accumulation and angiogenesis.","volume":"7","author":"Sakai","year":"2017","journal-title":"Sci. Rep."},{"key":"B199","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.19082\/3896","article-title":"Effectiveness of Coenzyme Q10 on echocardiographic parameters of patients with Duchenne muscular dystrophy.","volume":"9","author":"Salehi","year":"2017","journal-title":"Electron. Phys."},{"key":"B200","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1369\/jhc.4A6279.2004","article-title":"Corticotropin-releasing factor 2 receptor localization in skeletal muscle.","volume":"52","author":"Samuelsson","year":"2004","journal-title":"J. Histochem. Cytochem."},{"key":"B201","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1146\/annurev-virology-031413-085355","article-title":"AAV-mediated gene therapy for research and therapeutic purposes.","volume":"1","author":"Samulski","year":"2014","journal-title":"Annu. Rev. Virol."},{"key":"B202","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.1007\/s00198-012-1911-3","article-title":"The use of intravenous bisphosphonate therapy to treat vertebral fractures due to osteoporosis among boys with Duchenne muscular dystrophy.","volume":"23","author":"Sbrocchi","year":"2012","journal-title":"Osteoporos. Int."},{"key":"B203","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.2353\/ajpath.2007.070292","article-title":"Modulation of insulin-like growth factor (IGF)-I and IGF-binding protein interactions enhances skeletal muscle regeneration and ameliorates the dystrophic pathology in mdx mice.","volume":"171","author":"Schertzer","year":"2007","journal-title":"Am. J. Pathol."},{"key":"B204","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.molmet.2019.06.020","article-title":"Phosphatidylserine decarboxylase is critical for the maintenance of skeletal muscle mitochondrial integrity and muscle mass.","volume":"27","author":"Selathurai","year":"2019","journal-title":"Mol. Metab."},{"key":"B205","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.nmd.2019.10.008","article-title":"Long-term data with idebenone on respiratory function outcomes in patients with Duchenne muscular dystrophy.","volume":"30","author":"Servais","year":"2020","journal-title":"Neuromuscul. Disord."},{"key":"B206","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.ymthe.2004.07.026","article-title":"Targeted expression of insulin-like growth factor-I reduces early myofiber necrosis in dystrophic mdx mice.","volume":"10","author":"Shavlakadze","year":"2004","journal-title":"Mol. Ther."},{"key":"B207","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1126\/science.2662404","article-title":"The molecular basis of muscular dystrophy in the mdx mouse: a point mutation.","volume":"244","author":"Sicinski","year":"1989","journal-title":"Science"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011711.pub2","article-title":"Respiratory muscle training in children and adults with neuromuscular disease.","volume":"9","author":"Silva","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"B209","doi-asserted-by":"publisher","first-page":"12946","DOI":"10.1096\/fj.201902102RR","article-title":"cAMP-dependent protein kinase inhibits FoxO activity and regulates skeletal muscle plasticity in mice.","volume":"34","author":"Silveira","year":"2020","journal-title":"FASEB J."},{"key":"B210","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.3892\/etm.2017.4105","article-title":"Expression levels of TGF-\u03b21 and CTGF are associated with the severity of Duchenne muscular dystrophy.","volume":"13","author":"Song","year":"2017","journal-title":"Exp. Ther. Med."},{"key":"B211","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1080\/21678707.2016.1240613","article-title":"Pharmacological therapeutics targeting the secondary defects and downstream pathology of Duchenne muscular dystrophy.","volume":"4","author":"Spinazzola","year":"2016","journal-title":"Expert. Opin. Orphan Drugs"},{"key":"B212","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1002\/mus.22047","article-title":"CINRG pilot trial of coenzyme Q10 in steroid-treated Duchenne muscular dystrophy.","volume":"44","author":"Spurney","year":"2011","journal-title":"Muscle Nerve"},{"key":"B213","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.ymthe.2018.07.021","article-title":"Membrane stabilization by modified steroid offers a potential therapy for muscular dystrophy due to dysferlin deficit.","volume":"26","author":"Sreetama","year":"2018","journal-title":"Mol. Ther."},{"key":"B214","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/352536a0","article-title":"The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy.","volume":"352","author":"Stedman","year":"1991","journal-title":"Nature"},{"key":"B215","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1096\/fj.04-1859fje","article-title":"Glucocorticoid treatment alleviates dystrophic myofiber pathology by activation of the calcineurin\/NF-AT pathway.","volume":"18","author":"St-Pierre","year":"2004","journal-title":"FASEB J."},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2019.113086","article-title":"Stem cell-based therapies for Duchenne muscular dystrophy.","volume":"323","author":"Sun","year":"2020","journal-title":"Exp. Neurol."},{"key":"B217","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.apsb.2020.01.001","article-title":"Natural products, PGC-1 \u03b1, and Duchenne muscular dystrophy.","volume":"10","author":"Suntar","year":"2020","journal-title":"Acta Pharm. Sin B"},{"key":"B218","first-page":"9","article-title":"Clinical features of patients with dystrophinopathy sharing the 45-55 exon deletion of DMD gene.","volume":"34","author":"Taglia","year":"2015","journal-title":"Acta Myol."},{"key":"B219","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1002\/acn3.651","article-title":"A phase I study of TAS-205 in patients with Duchenne muscular dystrophy.","volume":"5","author":"Takeshita","year":"2018","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaz7492","article-title":"Gene therapy for follistatin mitigates systemic metabolic inflammation and post-traumatic arthritis in high-fat diet-induced obesity.","volume":"6","author":"Tang","year":"2020","journal-title":"Sci. Adv."},{"key":"B221","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/mus.21869","article-title":"Prevention of muscle fibrosis and myonecrosis in mdx mice by suramin, a TGF-\u03b21 blocker.","volume":"43","author":"Taniguti","year":"2011","journal-title":"Muscle Nerve"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0003644","article-title":"Inhibitory control over Ca(2+) sparks via mechanosensitive channels is disrupted in dystrophin deficient muscle but restored by mini-dystrophin expression.","volume":"3","author":"Teichmann","year":"2008","journal-title":"PLoS One"},{"key":"B223","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.nmd.2011.11.007","article-title":"N-Acetylcysteine treatment of dystrophic mdx mice results in protein thiol modifications and inhibition of exercise induced myofibre necrosis.","volume":"22","author":"Terrill","year":"2012","journal-title":"Neuromuscul. Disord."},{"key":"B224","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.nmd.2016.08.011","article-title":"Bone health measures in glucocorticoid-treated ambulatory boys with Duchenne muscular dystrophy.","volume":"26","author":"Tian","year":"2016","journal-title":"Neuromuscul. Disord."},{"key":"B225","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0019189","article-title":"Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse.","volume":"6","author":"Tinsley","year":"2011","journal-title":"PLoS One"},{"key":"B226","doi-asserted-by":"publisher","first-page":"563","DOI":"10.3727\/000000007783465064","article-title":"Autologous transplantation of muscle-derived CD133+ stem cells in Duchenne muscle patients.","volume":"16","author":"Torrente","year":"2007","journal-title":"Cell Transplant."},{"key":"B227","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1586\/14779072.5.1.99","article-title":"Cardiomyopathy of Duchenne muscular dystrophy: pathogenesis and prospect of membrane sealants as a new therapeutic approach.","volume":"5","author":"Townsend","year":"2007","journal-title":"Expert. Rev. Cardiovasc. Ther."},{"key":"B228","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.nmd.2008.06.386","article-title":"Prevention of muscle fibrosis and improvement in muscle performance in the mdx mouse by halofuginone.","volume":"18","author":"Turgeman","year":"2008","journal-title":"Neuromuscul. Disord."},{"key":"B229","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.scr.2017.10.023","article-title":"A human iPS cell myogenic differentiation system permitting high-throughput drug screening.","volume":"25","author":"Uchimura","year":"2017","journal-title":"Stem Cell Res."},{"key":"B230","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/s41582-019-0203-3","article-title":"Therapeutic developments for Duchenne muscular dystrophy.","volume":"15","author":"Verhaart","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"B231","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1212\/WNL.0000000000004570","article-title":"A phase 3 randomized placebo-controlled trial of tadalafil for Duchenne muscular dystrophy.","volume":"89","author":"Victor","year":"2017","journal-title":"Neurology"},{"key":"B232","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci11010115","article-title":"A phase 1\/2 study of flavocoxid, an oral nf-\u03bab inhibitor, in duchenne muscular dystrophy.","volume":"11","author":"Vita","year":"2021","journal-title":"Brain Sci."},{"key":"B233","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20236053","article-title":"Teaching an old molecule new tricks: drug repositioning for duchenne muscular dystrophy.","volume":"20","author":"Vitiello","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B234","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-56955-1","article-title":"Transcriptomic changes during TGF-\u03b2-mediated differentiation of airway fibroblasts to myofibroblasts.","volume":"9","author":"Walker","year":"2019","journal-title":"Sci. Rep."},{"key":"B235","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.braindev.2017.03.024","article-title":"The AAV-mediated and RNA-guided CRISPR\/Cas9 system for gene therapy of DMD and BMD.","volume":"39","author":"Wang","year":"2017","journal-title":"Brain Dev."},{"key":"B236","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13144-y","article-title":"The landscape of multiscale transcriptomic networks and key regulators in Parkinson\u2019s disease.","volume":"10","author":"Wang","year":"2019","journal-title":"Nat. Commun."},{"key":"B237","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/978-1-4939-9065-8_18","article-title":"Systemic delivery of adeno-associated viral vectors in mice and dogs.","volume":"1937","author":"Wasala","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"B238","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1007\/s00415-012-6512-8","article-title":"Permanent muscular sodium overload and persistent muscle edema in Duchenne muscular dystrophy: a possible contributor of progressive muscle degeneration.","volume":"259","author":"Weber","year":"2012","journal-title":"J. Neurol."},{"key":"B239","doi-asserted-by":"crossref","first-page":"10461","DOI":"10.3390\/ijms130810461","article-title":"Transforming growth factor-beta-induced protein (TGFBI)\/(\u00dfig-H3): a matrix protein with dual functions in ovarian cancer","volume":"13","author":"Ween","year":"2012","journal-title":"Int. J. Mol. Sci."},{"key":"B240","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3003921","article-title":"Recombinant MG53 protein modulates therapeutic cell membrane repair in treatment of muscular dystrophy.","volume":"4","author":"Weisleder","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"B241","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1113\/jphysiol.2007.148338","article-title":"N-Acetylcysteine ameliorates skeletal muscle pathophysiology in mdx mice.","volume":"586","author":"Whitehead","year":"2008","journal-title":"J. Physiol."},{"key":"B242","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.nmd.2006.07.024","article-title":"Streptomycin reduces stretch-induced membrane permeability in muscles from mdx mice.","volume":"16","author":"Whitehead","year":"2006","journal-title":"Neuromuscul. Disord."},{"key":"B243","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.nmd.2008.11.015","article-title":"Mammalian animal models for Duchenne muscular dystrophy.","volume":"19","author":"Willmann","year":"2009","journal-title":"Neuromuscul. Disord."},{"key":"B244","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1161\/ATVBAHA.107.151456","article-title":"PECAM-1: a multi-functional molecule in inflammation and vascular biology. Arterioscler","volume":"27","author":"Woodfin","year":"2007","journal-title":"Thromb. Vasc. Biol."},{"key":"B245","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1016\/j.celrep.2018.10.067","article-title":"A Myogenic Double-Reporter Human Pluripotent Stem Cell Line Allows Prospective Isolation of Skeletal Muscle Progenitors.","volume":"25","author":"Wu","year":"2018","journal-title":"Cell Rep."},{"key":"B246","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1172\/JCI31487","article-title":"Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases.","volume":"117","author":"Wynn","year":"2007","journal-title":"J. Clin. Invest."},{"key":"B247","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/path.2277","article-title":"Cellular and molecular mechanisms of fibrosis.","volume":"214","author":"Wynn","year":"2008","journal-title":"J. Pathol."},{"key":"B248","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2353\/ajpath.2009.080967","article-title":"Overexpression of Galgt2 reduces dystrophic pathology in the skeletal muscles of alpha sarcoglycan-deficient mice.","volume":"175","author":"Xu","year":"2009","journal-title":"Am. J. Pathol."},{"key":"B249","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.1016\/j.ajpath.2015.06.008","article-title":"Deletion of Galgt2 (B4Galnt2) reduces muscle growth in response to acute injury and increases muscle inflammation and pathology in dystrophin-deficient mice.","volume":"185","author":"Xu","year":"2015","journal-title":"Am. J. Pathol."},{"key":"B250","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.stemcr.2015.07.016","article-title":"Human satellite cell transplantation and regeneration from diverse skeletal muscles.","volume":"5","author":"Xu","year":"2015","journal-title":"Stem Cell Rep."},{"key":"B251","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1091\/mbc.11.10.3353","article-title":"Matricellular proteins as modulators of cell-matrix interactions: adhesive defect in thrombospondin 2-null fibroblasts is a consequence of increased levels of matrix metalloproteinase-2","volume":"11","author":"Yang","year":"2000","journal-title":"Mol. Biol. Cell"},{"key":"B252","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000001822","article-title":"Efficacy and safety of zoledronic acid and pamidronate disodium in the treatment of malignant skeletal metastasis: a meta-analysis.","volume":"94","author":"Yang","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"B253","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1113\/jphysiol.2004.075275","article-title":"Effects of stretch-activated channel blockers on [Ca2+]i and muscle damage in the mdx mouse.","volume":"562","author":"Yeung","year":"2005","journal-title":"J. Physiol."},{"key":"B254","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.stem.2016.01.021","article-title":"A single CRISPR-Cas9 deletion strategy that targets the majority of DMD patients restores dystrophin function in hiPSC-derived muscle cells.","volume":"18","author":"Young","year":"2016","journal-title":"Cell Stem Cell"},{"key":"B255","doi-asserted-by":"publisher","first-page":"388","DOI":"10.7150\/jca.31636","article-title":"TBX2 identified as a potential predictor of bone metastasis in lung adenocarcinoma via integrated bioinformatics analyses and verification of functional assay.","volume":"11","author":"Yu","year":"2020","journal-title":"J. Cancer"},{"key":"B256","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/(SICI)1097-4598(200004)23:4<521::AID-MUS10>3.0.CO;2-8","article-title":"Clenbuterol reduces degeneration of exercised or aged dystrophic (mdx) muscle.","volume":"23","author":"Zeman","year":"2000","journal-title":"Muscle Nerve"},{"key":"B257","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aay6812","article-title":"Enhanced CRISPR-Cas9 correction of Duchenne muscular dystrophy in mice by a self-complementary AAV delivery system.","volume":"6","author":"Zhang","year":"2020","journal-title":"Sci. Adv."},{"key":"B258","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.1602814","article-title":"CRISPR-Cpf1 correction of muscular dystrophy mutations in human cardiomyocytes and mice.","volume":"3","author":"Zhang","year":"2017","journal-title":"Sci. Adv."},{"key":"B259","doi-asserted-by":"publisher","first-page":"27439","DOI":"10.1039\/C8CP04226H","article-title":"Dynamics changes of CRISPR-Cas9 systems induced by high fidelity mutations.","volume":"20","author":"Zheng","year":"2018","journal-title":"Phys. Chem. Chem. Phys."},{"key":"B260","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1097\/NEN.0b013e3181e9a34b","article-title":"Targeting fibrosis in Duchenne muscular dystrophy.","volume":"69","author":"Zhou","year":"2010","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"B261","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0246507","article-title":"Biomarker-focused multi-drug combination therapy and repurposing trial in mdx mice.","volume":"16","author":"Ziemba","year":"2021","journal-title":"PLoS One"},{"key":"B262","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.pjnns.2014.10.004","article-title":"MLPA based detection of mutations in the dystrophin gene of 180 Polish families with Duchenne\/Becker muscular dystrophy.","volume":"48","author":"Zimowski","year":"2014","journal-title":"Neurol. Neurochir. Pol."},{"key":"B263","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.omtm.2019.10.005","article-title":"rAAVrh74.MCK.GALGT2 demonstrates safety and widespread muscle glycosylation after intravenous delivery in C57BL\/6J Mice.","volume":"15","author":"Zygmunt","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2021.689533\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T16:51:10Z","timestamp":1673110270000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2021.689533\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,19]]},"references-count":263,"alternative-id":["10.3389\/fcell.2021.689533"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2021.689533","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,19]]},"article-number":"689533"}}